UNITY Biotechnology, Inc. to Host Investor & Analyst Event on Cellular Senescence

- Event will be webcast live -

SAN FRANCISCO, Nov. 13, 2018 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that it will host an Investor & Analyst Event on Cellular Senescence on Tuesday, December 11, 2018 from 9:00 a.m. – 11:30 a.m. ET in New York, NY.

Leading experts will discuss the biology of cellular senescence and its relationship to aging and diseases associated with aging. UNITY leadership will also review the company’s approach to extending healthspan through the creation of senolytic medicines.

The event will feature presentations from the following experts in the field of cellular senescence:

• Judith Campisi, Ph.D. – Professor at the Buck Institute for Research on Aging; Senior Scientist at Lawrence Berkeley National Laboratory; National Academy of Sciences member
• Jan van Deursen, Ph.D. – Professor of Biochemistry and Molecular Biology at The Mayo Clinic; Professor of Pediatrics at The Mayo Clinic

A live webcast will be available through the Investors & Media section of UNITY’s website. An archived replay will be available for 90 days following the event. Pre-registration is required to attend in person. Institutional investors and analysts interested in attending the event in New York City can email ir@unitybiotechnology.com to receive additional information.

About UNITY
UNITY Biotechnology is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. UNITY's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related diseases, such as osteoarthritis, eye diseases and pulmonary diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter.

Investors
Endurance AdvisorsElizabeth Broderebroder@enduranceadvisors.com

Media
Austine Graff
707-593-6151
austine.graff@unitybiotechnology.com

Source: Unity Biotechnology, Inc.